154 related articles for article (PubMed ID: 35583124)
1. A Class of Shark-Derived Single-Domain Antibodies can Broadly Neutralize SARS-Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape.
Feng B; Chen Z; Sun J; Xu T; Wang Q; Yi H; Niu X; Zhu J; Fan M; Hou R; Shao Y; Huang S; Li C; Hu P; Zheng P; He P; Luo J; Yan Q; Xiong X; Liu J; Zhao J; Chen L
Small Methods; 2022 Jul; 6(7):e2200387. PubMed ID: 35583124
[TBL] [Abstract][Full Text] [Related]
2. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity.
Chen WH; Hajduczki A; Martinez EJ; Bai H; Matz H; Hill TM; Lewitus E; Chang WC; Dawit L; Peterson CE; Rees PA; Ajayi AB; Golub ES; Swafford I; Dussupt V; David S; Mayer SV; Soman S; Kuklis C; Corbitt C; King J; Choe M; Sankhala RS; Thomas PV; Zemil M; Wieczorek L; Hart T; Duso D; Kummer L; Yan L; Sterling SL; Laing ED; Broder CC; Williams JK; Davidson E; Doranz BJ; Krebs SJ; Polonis VR; Paquin-Proulx D; Rolland M; Reiley WW; Gromowski GD; Modjarrad K; Dooley H; Joyce MG
Nat Commun; 2023 Feb; 14(1):580. PubMed ID: 36737435
[TBL] [Abstract][Full Text] [Related]
3. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
4. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.
Ma H; Zhang X; Zheng P; Dube PH; Zeng W; Chen S; Cheng Q; Yang Y; Wu Y; Zhou J; Hu X; Xiang Y; Zhang H; Chiu S; Jin T
Cell Res; 2022 Sep; 32(9):831-842. PubMed ID: 35906408
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.
Huang KA; Chen X; Mohapatra A; Nguyen HTV; Schimanski L; Tan TK; Rijal P; Vester SK; Hills RA; Howarth M; Keeffe JR; Cohen AA; Kakutani LM; Wu YM; Shahed-Al-Mahmud M; Chou YC; Bjorkman PJ; Townsend AR; Ma C
Nat Commun; 2023 Jan; 14(1):311. PubMed ID: 36658148
[TBL] [Abstract][Full Text] [Related]
6. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
7. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
[TBL] [Abstract][Full Text] [Related]
8. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
9. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
[TBL] [Abstract][Full Text] [Related]
10. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants.
Wang Y; Yan A; Song D; Duan M; Dong C; Chen J; Jiang Z; Gao Y; Rao M; Feng J; Zhang Z; Qi R; Ma X; Liu H; Yu B; Wang Q; Zong M; Jiao J; Xing P; Pan R; Li D; Xiao J; Sun J; Li Y; Zhang L; Shen Z; Sun B; Zhao Y; Zhang L; Dai J; Zhao J; Wang L; Dou C; Liu Z; Zhao J
Nat Commun; 2024 Jan; 15(1):842. PubMed ID: 38287016
[TBL] [Abstract][Full Text] [Related]
11. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants.
Jeong BS; Cha JS; Hwang I; Kim U; Adolf-Bryfogle J; Coventry B; Cho HS; Kim KD; Oh BH
MAbs; 2022; 14(1):2021601. PubMed ID: 35030983
[TBL] [Abstract][Full Text] [Related]
12. Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies.
Li R; Mor M; Ma B; Clark AE; Alter J; Werbner M; Lee JC; Leibel SL; Carlin AF; Dessau M; Gal-Tanamy M; Croker BA; Xiang Y; Freund NT
Commun Biol; 2022 Aug; 5(1):789. PubMed ID: 35931732
[TBL] [Abstract][Full Text] [Related]
13. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
Li M; Ren Y; Aw ZQ; Chen B; Yang Z; Lei Y; Cheng L; Liang Q; Hong J; Yang Y; Chen J; Wong YH; Wei J; Shan S; Zhang S; Ge J; Wang R; Dong JZ; Chen Y; Shi X; Zhang Q; Zhang Z; Chu JJH; Wang X; Zhang L
Nat Commun; 2022 Dec; 13(1):7957. PubMed ID: 36575191
[TBL] [Abstract][Full Text] [Related]
14. Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron.
Liu H; Kaku CI; Song G; Yuan M; Andrabi R; Burton DR; Walker LM; Wilson IA
Commun Biol; 2022 Jul; 5(1):766. PubMed ID: 35906394
[TBL] [Abstract][Full Text] [Related]
15. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Omicron variant emerged under immune selection.
Tan CW; Chia WN; Zhu F; Young BE; Chantasrisawad N; Hwa SH; Yeoh AY; Lim BL; Yap WC; Pada SKMS; Tan SY; Jantarabenjakul W; Toh LK; Chen S; Zhang J; Mah YY; Chen VC; Chen MI; Wacharapluesadee S; Sigal A; Putcharoen O; Lye DC; Wang LF
Nat Microbiol; 2022 Nov; 7(11):1756-1761. PubMed ID: 36195753
[TBL] [Abstract][Full Text] [Related]
17. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
18. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination.
Chi X; Guo Y; Zhang G; Sun H; Zhang J; Li M; Chen Z; Han J; Zhang Y; Zhang X; Fan P; Zhang Z; Wang B; Zai X; Han X; Hao M; Fang T; Xu J; Wu S; Chen Y; Fang Y; Dong Y; Sun B; Zhang J; Li J; Zhao G; Yu C; Zhou Q; Chen W
Signal Transduct Target Ther; 2022 Apr; 7(1):139. PubMed ID: 35478188
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
20. Cryo-EM structure of the SARS-CoV-2 Omicron spike.
Cerutti G; Guo Y; Liu L; Liu L; Zhang Z; Luo Y; Huang Y; Wang HH; Ho DD; Sheng Z; Shapiro L
Cell Rep; 2022 Mar; 38(9):110428. PubMed ID: 35172173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
